Mahesh Karande. (World Economic Forum / Jakob Polacsek)
New Flagship biotech wants to unleash your genome
It sounds like tacky science fiction when Mahesh Karande talks about it, like a line from that movie with the pill promising to unlock the other 90% of your brain. The company “is unleashing the human genome’s native capacity,” he says.
His voice, normally deep and measured, scientific in its precision, rushes as he talks about his new biotech, his diction bouncing with schoolboy slang.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
